These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 12036915

  • 1. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels.
    Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R.
    Cancer Res; 2002 Jun 01; 62(11):3063-9. PubMed ID: 12036915
    [Abstract] [Full Text] [Related]

  • 2. Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis.
    Singh RP, Sharma G, Dhanalakshmi S, Agarwal C, Agarwal R.
    Cancer Epidemiol Biomarkers Prev; 2003 Sep 01; 12(9):933-9. PubMed ID: 14504208
    [Abstract] [Full Text] [Related]

  • 3. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.
    Singh RP, Deep G, Blouin MJ, Pollak MN, Agarwal R.
    Carcinogenesis; 2007 Dec 01; 28(12):2567-74. PubMed ID: 17916909
    [Abstract] [Full Text] [Related]

  • 4. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis.
    Tyagi AK, Singh RP, Agarwal C, Chan DC, Agarwal R.
    Clin Cancer Res; 2002 Nov 01; 8(11):3512-9. PubMed ID: 12429642
    [Abstract] [Full Text] [Related]

  • 5. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells.
    Zi X, Zhang J, Agarwal R, Pollak M.
    Cancer Res; 2000 Oct 15; 60(20):5617-20. PubMed ID: 11059749
    [Abstract] [Full Text] [Related]

  • 6. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
    Zi X, Grasso AW, Kung HJ, Agarwal R.
    Cancer Res; 1998 May 01; 58(9):1920-9. PubMed ID: 9581834
    [Abstract] [Full Text] [Related]

  • 7. Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells.
    Tyagi A, Bhatia N, Condon MS, Bosland MC, Agarwal C, Agarwal R.
    Prostate; 2002 Nov 01; 53(3):211-7. PubMed ID: 12386921
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic value of orally administered silibinin in renal cell carcinoma: manipulation of insulin-like growth factor binding protein-3 levels.
    Cheung CW, Taylor PJ, Kirkpatrick CM, Vesey DA, Gobe GC, Winterford C, Nicol DL, Johnson DW.
    BJU Int; 2007 Aug 01; 100(2):438-44. PubMed ID: 17617146
    [Abstract] [Full Text] [Related]

  • 9. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin.
    Singh RP, Tyagi A, Sharma G, Mohan S, Agarwal R.
    Clin Cancer Res; 2008 Jan 01; 14(1):300-8. PubMed ID: 18172282
    [Abstract] [Full Text] [Related]

  • 10. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model.
    Raina K, Blouin MJ, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R.
    Cancer Res; 2007 Nov 15; 67(22):11083-91. PubMed ID: 18006855
    [Abstract] [Full Text] [Related]

  • 11. Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.
    Singh RP, Mallikarjuna GU, Sharma G, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R.
    Clin Cancer Res; 2004 Dec 15; 10(24):8641-7. PubMed ID: 15623648
    [Abstract] [Full Text] [Related]

  • 12. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
    Xu X, Kreye E, Kuo CB, Walker AM.
    Cancer Res; 2001 Aug 15; 61(16):6098-104. PubMed ID: 11507059
    [Abstract] [Full Text] [Related]

  • 13. Silibinin inhibits renal cell carcinoma via mechanisms that are independent of insulin-like growth factor-binding protein 3.
    Cheung CW, Vesey DA, Nicol DL, Johnson DW.
    BJU Int; 2007 Feb 15; 99(2):454-60. PubMed ID: 17313429
    [Abstract] [Full Text] [Related]

  • 14. Silibinin upregulates the expression of cyclin-dependent kinase inhibitors and causes cell cycle arrest and apoptosis in human colon carcinoma HT-29 cells.
    Agarwal C, Singh RP, Dhanalakshmi S, Tyagi AK, Tecklenburg M, Sclafani RA, Agarwal R.
    Oncogene; 2003 Nov 13; 22(51):8271-82. PubMed ID: 14614451
    [Abstract] [Full Text] [Related]

  • 15. Prostate cancer chemoprevention by silibinin: bench to bedside.
    Singh RP, Agarwal R.
    Mol Carcinog; 2006 Jun 13; 45(6):436-42. PubMed ID: 16637061
    [Abstract] [Full Text] [Related]

  • 16. In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells.
    Nambiar D, Prajapati V, Agarwal R, Singh RP.
    Cancer Lett; 2013 Jun 28; 334(1):109-17. PubMed ID: 23022268
    [Abstract] [Full Text] [Related]

  • 17. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
    Deep G, Singh RP, Agarwal C, Kroll DJ, Agarwal R.
    Oncogene; 2006 Feb 16; 25(7):1053-69. PubMed ID: 16205633
    [Abstract] [Full Text] [Related]

  • 18. The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
    Jackson JK, Gleave ME, Yago V, Beraldi E, Hunter WL, Burt HM.
    Cancer Res; 2000 Aug 01; 60(15):4146-51. PubMed ID: 10945622
    [Abstract] [Full Text] [Related]

  • 19. Silibinin inhibits the invasion and migration of renal carcinoma 786-O cells in vitro, inhibits the growth of xenografts in vivo and enhances chemosensitivity to 5-fluorouracil and paclitaxel.
    Chang HR, Chen PN, Yang SF, Sun YS, Wu SW, Hung TW, Lian JD, Chu SC, Hsieh YS.
    Mol Carcinog; 2011 Oct 01; 50(10):811-23. PubMed ID: 21574189
    [Abstract] [Full Text] [Related]

  • 20. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.
    Davis-Searles PR, Nakanishi Y, Kim NC, Graf TN, Oberlies NH, Wani MC, Wall ME, Agarwal R, Kroll DJ.
    Cancer Res; 2005 May 15; 65(10):4448-57. PubMed ID: 15899838
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.